HPGD | OmnibusX

I. Expression across cell types

Name	Number of supported studies	Average coverage
mast cell	34 studies	58% ± 20%	Explore
epithelial cell	10 studies	38% ± 17%	Explore
enterocyte	7 studies	35% ± 8%	Explore
capillary endothelial cell	7 studies	59% ± 14%	Explore
regulatory T cell	7 studies	23% ± 9%	Explore
secretory cell	6 studies	29% ± 8%	Explore
CD4-positive, alpha-beta T cell	6 studies	24% ± 7%	Explore
alveolar macrophage	6 studies	37% ± 14%	Explore
endothelial cell	5 studies	43% ± 16%	Explore
hepatocyte	4 studies	36% ± 13%	Explore
basal cell	3 studies	32% ± 6%	Explore
epithelial cell of proximal tubule	3 studies	19% ± 3%	Explore
goblet cell	3 studies	21% ± 2%	Explore
extravillous trophoblast	3 studies	53% ± 15%	Explore
granulocyte	3 studies	43% ± 27%	Explore
CD8-positive, alpha-beta T cell	3 studies	24% ± 9%	Explore

II. Expression across tissues

Name	Number of supported studies	Average coverage
lung	3 studies	29% ± 8%	Explore
intestine	3 studies	21% ± 4%	Explore

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
intestine	98%	5819.04	943 / 966	75%	20.95	394 / 527
stomach	97%	4425.12	349 / 359	72%	21.25	205 / 286
lung	99%	6657.40	572 / 578	69%	48.06	793 / 1155
bladder	90%	7167.90	19 / 21	73%	123.89	366 / 504
liver	100%	6173.86	226 / 226	60%	39.18	244 / 406
esophagus	95%	4772.13	1367 / 1445	58%	17.82	106 / 183
uterus	89%	3797.59	152 / 170	45%	25.61	206 / 459
prostate	65%	963.00	159 / 245	69%	42.60	345 / 502
skin	72%	3137.47	1296 / 1809	55%	38.78	258 / 472
kidney	83%	1828.43	74 / 89	31%	6.83	280 / 901
ureter	0%	0	0 / 0	100%	74.94	1 / 1
pancreas	0%	1.85	1 / 328	86%	39.26	153 / 178
adrenal gland	35%	754.97	90 / 258	35%	15.85	80 / 230
spleen	67%	934.93	162 / 241	0%	0	0 / 0
breast	41%	649.58	186 / 459	21%	10.82	237 / 1118
adipose	56%	915.02	671 / 1204	0%	0	0 / 0
tonsil	0%	0	0 / 0	47%	9.11	21 / 45
peripheral blood	43%	2997.54	398 / 929	0%	0	0 / 0
ovary	9%	103.06	16 / 180	27%	13.66	117 / 430
eye	0%	0	0 / 0	28%	7.85	22 / 80
thymus	1%	4.15	4 / 653	15%	3.35	89 / 605
lymph node	0%	0	0 / 0	7%	0.46	2 / 29
muscle	4%	45.02	36 / 803	0%	0	0 / 0
blood vessel	2%	26.50	31 / 1335	0%	0	0 / 0
brain	0%	1.69	5 / 2642	0%	0.04	2 / 705
heart	0%	0.79	1 / 861	0%	0	0 / 0
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
gingiva	0%	0	0 / 0	0%	0	0 / 0
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0

III. Associated gene sets

GO_0032355	Biological process	response to estradiol
GO_1905828	Biological process	regulation of prostaglandin catabolic process
GO_0045786	Biological process	negative regulation of cell cycle
GO_0019372	Biological process	lipoxygenase pathway
GO_0001822	Biological process	kidney development
GO_0070493	Biological process	thrombin-activated receptor signaling pathway
GO_0032496	Biological process	response to lipopolysaccharide
GO_0045471	Biological process	response to ethanol
GO_0007565	Biological process	female pregnancy
GO_0030728	Biological process	ovulation
GO_0006693	Biological process	prostaglandin metabolic process
GO_0097070	Biological process	ductus arteriosus closure
GO_0007179	Biological process	transforming growth factor beta receptor signaling pathway
GO_0043065	Biological process	positive regulation of apoptotic process
GO_1904707	Biological process	positive regulation of vascular associated smooth muscle cell proliferation
GO_0007567	Biological process	parturition
GO_0070062	Cellular component	extracellular exosome
GO_0005654	Cellular component	nucleoplasm
GO_0005829	Cellular component	cytosol
GO_0005737	Cellular component	cytoplasm
GO_0016323	Cellular component	basolateral plasma membrane
GO_0004957	Molecular function	prostaglandin E receptor activity
GO_0051287	Molecular function	NAD binding
GO_0042802	Molecular function	identical protein binding
GO_0070403	Molecular function	NAD+ binding
GO_0016404	Molecular function	15-hydroxyprostaglandin dehydrogenase (NAD+) activity
GO_0016616	Molecular function	oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor

IV. Literature review

[source]

Gene name	HPGD
Protein name	15-hydroxyprostaglandin dehydrogenase 15-hydroxyprostaglandin dehydrogenase [NAD(+)] (15-PGDH) (EC 1.1.1.141) (Eicosanoid/docosanoid dehydrogenase [NAD(+)]) (EC 1.1.1.-, EC 1.1.1.232) (Prostaglandin dehydrogenase 1) (Short chain dehydrogenase/reductase family 36C member 1) 15-hydroxyprostaglandin dehydrogenase [NAD(+)] (EC 1.1.1.141) (EC 1.1.1.232) (Eicosanoid/docosanoid dehydrogenase [NAD(+)]) (Prostaglandin dehydrogenase 1)
Synonyms	SDR36C1 PGDH1
Description	FUNCTION: Catalyzes the NAD-dependent dehydrogenation (oxidation) of a broad array of hydroxylated polyunsaturated fatty acids (mainly eicosanoids and docosanoids, including prostaglandins, lipoxins and resolvins), yielding their corresponding keto (oxo) metabolites . Decreases the levels of the pro-proliferative prostaglandins such as prostaglandin E2 (whose activity is increased in cancer because of an increase in the expression of cyclooxygenase 2) and generates oxo-fatty acid products that can profoundly influence cell function by abrogating pro-inflammatory cytokine expression . Converts resolvins E1, D1 and D2 to their oxo products, which represents a mode of resolvin inactivation. Resolvin E1 plays important roles during the resolution phase of acute inflammation, while resolvins D1 and D2 have a unique role in obesity-induced adipose inflammation . .
Accessions	E9PBZ2 ENST00000508330.5 D6RHF8 ENST00000422112.6 [P15428-5] D6RA66 ENST00000510835.5 ENST00000541923.5 [P15428-3] P15428 ENST00000510901.5 [P15428-3] ENST00000506910.5 ENST00000542498.5 [P15428-4] ENST00000504433.1 E9PD69 ENST00000296522.11 [P15428-1] D6RA83 ENST00000514584.5 ENST00000296521.11 [P15428-2]

HPGD report

I. Expression across cell types

II. Expression across tissues

III. Associated gene sets

IV. Literature review